secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
CIK:        0000315545
Form:       8-K
Filed at:   2026-06-30T23:37:26+00:00
Accession:  0001493152-26-031379
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Provectus Biopharmaceuticals converts $542,500 in accrued director fees into Series D-1 Preferred Stock
--------------------------------------------------------------------------------

- Board approved conversion of $542,500 in accrued directors' fees into 189,554 shares of Series D-1 Preferred Stock.
- Preferred Stock is convertible into 1,895,540 shares of Common Stock.
- Issuance satisfies outstanding cash fees, not under 2024 Equity Compensation Plan.
- Conversion effective as of June 30, 2026, based on May 14, 2026 Board approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/315545/000149315226031379/0001493152-26-031379-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/315545/000149315226031379/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-031379

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer